Product
Hetrombopag
10 clinical trials
8 indications
Indication
Chemotherapy-Induced ThrombocytopeniaIndication
Immune ThrombocytopeniaIndication
Chemotherapy-induced ThrombocytopeniaIndication
ThrombocytopeniaIndication
HepatopathyIndication
Breast CancerIndication
Hematological DisorderClinical trial
Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Hetrombopag for the Treatment of Chemotherapy-induced Thrombocytopenia in Adults With Solid Tumors.Status: Not yet recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Stage Phase Ⅲ Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets in Treatment of Chemotherapy-Induced ThrombocytopeniaStatus: Withdrawn, Estimated PCD: 2025-03-15
Clinical trial
High-dose Dexamethasone Plus Hetrombopag Versus High-dose Dexamethasone Alone as Frontline Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia (ITP):A Prospective Multicenter Randomized TrialStatus: Recruiting, Estimated PCD: 2024-07-10
Clinical trial
The Efficacy and Safety of Hetrombopag as Secondary Prevention to Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Malignancies（the SPRIT TRIAL）Status: Not yet recruiting, Estimated PCD: 2025-09-15
Clinical trial
The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer PatientsStatus: Not yet recruiting, Estimated PCD: 2025-07-15
Clinical trial
Director, Department of Liver Surgery, Fudan University Shanghai Cancer CenterStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
An Open, Single-center, Phase II Clinical Study of Hetrombopag in Secondary Prevention of XPO-1 Inhibitor Selinexor Combined With Chemotherapy Induced Thrombocytopenia in LymphomaStatus: Not yet recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Single-center, Randomized, Self-controlled Exploratory Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Chemotherapy in Advanced Breast CancerStatus: Recruiting, Estimated PCD: 2024-12-28
Clinical trial
Efficacy and Safety of Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological DiseaseStatus: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
Thrombopoietin Receptor Agonist (TPO-RA) Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment TerminationStatus: Recruiting, Estimated PCD: 2027-06-20